Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

TUESDAY, July 1, 2025 (HealthDay News) -- For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction ...

When weeds start popping up between cracks, it's time to intervene. Easily stop them in their tracks and keep the area weed-free with a DIY vinegar solution.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

From 23 June 2025, Tirzepatide must be implemented in primary care. Tirzepatide represents a new therapy for weight management, but requires structured implementation, appropriate monitoring, and ...

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions Jun. 16, 2025 6:45 AM ET Eli Lilly and Company (LLY) ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in ...

Beyond that, Lilly still needs to share data from a phase 1 eloralintide-tirzepatide combination study it started in April and show whether weight loss continues to deepen beyond Week 12.